Aura Biosciences Reports Q3 2026 Loss of $32.1 Million and GAAP EPS of -$0.29, Exceeding Estimates
Loss per share of $0.29 beats the estimated $0.37 as Phase 3 enrollment completes Related Stocks: AURA ,
Loss per share of $0.29 beats the estimated $0.37 as Phase 3 enrollment completes Related Stocks: AURA ,